BioMarin acquires Prosensa Holding N.V. for $680 million
Clients BioMarin Pharmaceutical Inc.
Jones Day advised BioMarin Pharmaceutical Inc. in its acquisition of Prosensa Holding N.V., a public, biotechnology company, focused on the discovery and development of RNA-modulating therapeutics for the treatment of rare genetic disorders. The transaction consideration consisted of an up front cash payment of $680 million and achievement of two future regulatory milestones in an aggregate amount equal of $160 million.
In addition to M&A representation, Jones Day provided tax, regulatory, antitrust, employee benefits, and intellectual property advice regarding this transaction.